Feb
22
Written by:
Steve Patterson
2/22/2008 3:25 PM
Genetech Inc. (DNA) March options in the 70, 75,
and 80 calls are being purchased with high volume today ahead of a FDA
decision. Genetech investors are awaiting the FDA’s decision on weather to
allow Avastin for breast cancer treatments, which could be released sometime
today. The FDA Advisory Committee voted 5-4 against recommending approval of
Avastin for breast cancer treatment. Rumors are that two members who voted
against the decision have reconsidered their positions. Playing it safe and
still getting the upside if the FDA votes in favor of Genetech, you would
purchase some March 70 calls.
Tags: